BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15252171)

  • 1. High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases.
    Schönholzer C; Keusch G; Nigg L; Robert D; Wauters JP
    Nephrol Dial Transplant; 2004 Aug; 19(8):2121-5. PubMed ID: 15252171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure red cell aplasia due to treatment with epoietin beta: first case report of PRCA from Poland.
    Sułowicz W; Bentkowski W; Stompór T; Gross J; Biłyk A; Rudzki Z
    Przegl Lek; 2006; 63(9):810-4. PubMed ID: 17479877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
    Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.
    Stoffel MP; Haverkamp H; Kromminga A; Lauterbach KW; Baldamus CA
    Nephron Clin Pract; 2007; 105(2):c90-8. PubMed ID: 17164586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pure red cell aplasia in patient affected by myelodysplastic syndrome treated with R-Epo].
    Luraschi A; Montanara S; Fedeli P; Buscaglia P; Fossati O; Cozzi S; Castello A
    Recenti Prog Med; 2008 May; 99(5):255-7. PubMed ID: 18581968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pure red cell aplasia secondary to treatment with erythropoietin.
    Locatelli F; Del Vecchio L
    J Nephrol; 2003; 16(4):461-6. PubMed ID: 14696747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies.
    Yang J; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Lee JS
    J Nephrol; 2005; 18(1):102-5. PubMed ID: 15772931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients.
    Kharagjitsingh AV; Korevaar JC; Vandenbroucke JP; Boeschoten EW; Krediet RT; Daha MR; Dekker FW;
    Kidney Int; 2005 Sep; 68(3):1215-22. PubMed ID: 16105053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pure red-cell aplasia in a peritoneal dialysis patient with HCV-related cryoglobulinemia in the absence of neutralizing antierythropoietin antibodies.
    Aterini S; Fusco I; Amato M
    J Nephrol; 2004; 17(5):744-6. PubMed ID: 15593045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
    Opatrný K
    Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of biologic follow-ons: experience with EPO.
    Casadevall N; Rossert J
    Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to cyclosporine A in a patient with pure red cell aplasia due to antierythropoietin-alpha antibodies.
    Fraer M; Campbell A; Sawaya BP
    Semin Dial; 2006; 19(3):251-4. PubMed ID: 16689978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is antibody-mediated pure red cell aplasia (PRCA)?
    Casadevall N
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv3-8. PubMed ID: 15827056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.
    Evens AM; Bennett CL; Luminari S
    Best Pract Res Clin Haematol; 2005; 18(3):481-9. PubMed ID: 15792923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged course of pure red cell aplasia after erythropoietin therapy.
    Nigg L; Schanz U; Ambühl PM; Fehr J; Bachli EB
    Eur J Haematol; 2004 Nov; 73(5):376-9. PubMed ID: 15458518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to recombinant human erythropoietin causing pure red cell aplasia.
    Prabhakar SS; Muhlfelder T
    Clin Nephrol; 1997 May; 47(5):331-5. PubMed ID: 9181281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pure red cell aplasia (PRCA) induced by anti-EPO antibodies: epidemiology, diagnosis and treatment].
    Janda K; Kraśniak A; Krzanowski M; Sułowicz W
    Przegl Lek; 2010; 67(3):187-91. PubMed ID: 20687383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge.
    Smalling R; Foote M; Molineux G; Swanson SJ; Elliott S
    Biotechnol Annu Rev; 2004; 10():237-50. PubMed ID: 15504708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
    Macdougall IC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv9-15. PubMed ID: 15827058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.